Vemurafenib oral bioavailability: An insoluble problem

Journal of Clinical Pharmacology

Volumn 54, Issue 4, 2014, Pages 375-377

  Szmulewitz, Russell Z ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

bioavailability; food effect; melanoma; pharmacokinetics; Vemurafenib

Indexed keywords

VEMURAFENIB;

AREA UNDER THE CURVE; BIOAVAILABILITY; DRUG CLEARANCE; FOOD INTAKE; HUMAN; HYPOTENSION; MAXIMUM PLASMA CONCENTRATION; METASTATIC MELANOMA; PH; REVIEW; TACHYCARDIA;

ANTINEOPLASTIC AGENTS; DIETARY FATS; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; INDOLES; MALE; MELANOMA; PROTEIN KINASE INHIBITORS; SULFONAMIDES;

EID: 84898626787     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.277     Document Type: Review

References (10)

1. Ribas A, Zhang W, Chang I, et al. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol. 2014.
2. ZELBORAF® (vemurafenib) tablet oral prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/202429s002s003lbl.pdf. Accessed February 11, 2014.
3. Grippo JF, Zhang W, Heinzmann D, et al. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF (V600E) mutation-positive metastatic melanoma. Cancer Chemother Pharmacol. 2014; 73 (1): 103-111.
4. Shah N, Iyer RM, Mair HJ, et al. Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process. J Pharm Sci. 2013; 102 (3): 967-981.
5. Food and Drug Administration, Center for Drug Evaluation and Research. Application number: 202429Orig1s000. Clinical Pharmacology and Biopharmaceutics Review(s). Zelboraf. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/ 202429Orig1s000ClinPharmR.pdf. Accessed February 11, 2014.
6. Gu CH, Li H, Levons J, et al. Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res. 2007; 24 (6): 1118-1130. (Pubitemid 46798891)
7. Kang SP, Ratain MJ,. Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res. 2010; 16 (17): 4446-4451.
8. Szmulewitz RZ, Ratain MJ,. Playing Russian roulette with tyrosine kinase inhibitors. Clin Pharmacol Ther. 2013; 93 (3): 242-244.
9. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363 (9): 809-819.
10. Ratain MJ,. Flushing oral oncology drugs down the toilet. J Clin Oncol. 2011; 29 (30): 3958-3959.